Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.42 |
| ▸ | GBA1 | P04062 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9769271 | 0.87 | GBA1 (0.47) | BCHEACHEGBA1ALOX5PTGS1 | |
| SCHEMBL31093244 | 0.87 | GBA1 (0.47) | BCHEACHEGBA1ALOX5PTGS1 | |
| SCHEMBL31093212 | 0.87 | GBA1 (0.47) | BCHEACHEGBA1ALOX5PTGS1 | |
| SCHEMBL9617015 | 0.87 | GBA1 (0.47) | BCHEACHEGBA1ALOX5PTGS1 | |
| SCHEMBL9769185 | 0.87 | GBA1 (0.47) | BCHEACHEGBA1ALOX5PTGS1 | |
| SCHEMBL4421172 | 0.85 | GBA1 (0.44) | BCHEACHEGBA1ALOX5PTGS1 | |
| SCHEMBL8392265 | 0.83 | GBA1 (0.45) | BCHEACHEGBA1ALOX5PTGS1 | |
| SCHEMBL20912198 | 0.82 | KDM4E (0.39) | BCHEACHE | |
| SCHEMBL17836960 | 0.80 | ALOX5 (0.47) | BCHEACHEGBA1ALOX5PTGS1 | |
| SCHEMBL4424409 | 0.79 | MEN1 (0.45) | BCHEACHEGBA1ALOX5MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20200339583-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339583-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | BCHE 4578/4885ACHE 4767/4885DNM1 1625/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | BCHE 4578/4885ACHE 4767/4885DNM1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.